|
|
|
Home |
Products |
A
| Site Search
| Patient Education
|
|
A
> Aphthasol (Generic:5% Amlexanox oral paste)
Indicated for the treatment of aphthous ulcers in people with normal immune systems. |
References
|
The efficacy of amlexanox OraDisc on the prevention of recurrent minor aphthous ulceration
BACKGROUND: The study was designed to determine the efficacy of OraDisc (active component 2 mg amlexanox) on the prevention of aphthous ulcers treated at the prodromal stage. METHODS: Thermographic imaging was used to confirm the presence of a prodromal ulcer. Fifty-two patients were randomized to receive OraDisc (N = 26) or vehicle patches (N = 26). Patches were applied four times a day for 72 h over the prodromal area. The percentage of subjects who developed an ulcer at 72 h was compared between groups using the Fisher's exact test. RESULTS: About 50% of subjects in the OraDisc group developed an ulcer by day 4 compared with 69% in the vehicle group. Erythema score, ulcer size, pain scores and thermographically active area and temperature all showed trends towards healing in the OraDisc group. CONCLUSION: The OraDisc prevents ulcers from developing when compared with the vehicle patch. |
|
A comparative study of the efficacy of Aphtheal in the management of recurrent minor aphthous ulceration
BACKGROUND: Recurrent minor aphthous ulceration (RAU) is a common condition which is multifactorial in origin. METHODS: This study, firstly, aimed to treat the prodromal stage of RAU with Aphtheal (5% amlexanox paste) to determine if ulcer development could be prevented. A second arm of the study investigated treatment of RAU with Aphtheal once ulceration had developed. Ulcer duration, ulcer size and associated pain were measured. Both groups of subjects had previously undergone a no-treatment run-in period to establish these parameters over an untreated episode of ulceration. RESULTS: By day 3, only 35% of the prodromal group had developed an ulcer compared with 97% of the ulcer group (P < 0.001). In the treated ulcer group only 66% had an ulcer present by day 3. Treatment at the onset of prodromal symptoms reduced the maximum ulcer size score by 84% (P < 0.01), extent of ulceration by 88% (P < 0.01), maximum pain score by 69% (P < 0.01) and extent of pain by 85% (P < 0.01) compared to no treatment. CONCLUSION: Treatment with Aphtheal at the onset of prodromal RAU symptoms can prevent progression to ulcer development and significantly reduced symptoms if ulcers do develop. |
|
Selecting topical and systemic agents for recurrent aphthous stomatitis. (Cutis. 2001 Sep;68(3):201-6.) >Abstract >Related Articles Amlexanox oral paste: a novel treatment that accelerates the healing of aphthous ulcers. (Compend Contin Educ Dent. 1997 Nov;18(11):1116-8, 1120-2, 1124 passim.) >Abstract >Related Articles 5% amlexanox oral paste, a new treatment for recurrent minor aphthous ulcers: I. Clinical demonstration of acceleration of healing and resolution of pain. (Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Feb;83(2):222-30.) >Abstract >Related Articles 5% amlexanox oral paste, a new treatment for recurrent minor aphthous ulcers: II. Pharmacokinetics and demonstration of clinical safety. (Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Feb;83(2):231-8.) >Abstract >Related Articles A double-blind study of topically applied 5% amlexanox in the treatment of aphthous ulcers. (J Oral Maxillofac Surg. 1993 Mar;51(3):243-8; discussion 248-9.) >Abstract >Related Articles |
